Evaluation of Amide Proton Transfer-Weighted Imaging for Risk Factors in Stage I Endometrial Cancer: A Comparison With Diffusion-Weighted Imaging and Diffusion Kurtosis Imaging

Background: Endometrial cancer (EC) is one of the most common gynecologic malignancies in clinical practice. This study aimed to compare the value of diffusion-weighted imaging (DWI), diffusion kurtosis imaging (DKI), and amide proton transfer-weighted imaging (APTWI) in the assessment of risk strat...

Full description

Bibliographic Details
Main Authors: Guo, J. (Author), Han, D. (Author), Jin, X. (Author), Li, Z. (Author), Liu, W. (Author), Wang, H. (Author), Wang, K. (Author), Yan, R. (Author), Zhang, G. (Author), Zhang, M. (Author)
Format: Article
Language:English
Published: Frontiers Media S.A. 2022
Subjects:
Online Access:View Fulltext in Publisher
LEADER 03465nam a2200301Ia 4500
001 10.3389-fonc.2022.876120
008 220510s2022 CNT 000 0 und d
020 |a 2234943X (ISSN) 
245 1 0 |a Evaluation of Amide Proton Transfer-Weighted Imaging for Risk Factors in Stage I Endometrial Cancer: A Comparison With Diffusion-Weighted Imaging and Diffusion Kurtosis Imaging 
260 0 |b Frontiers Media S.A.  |c 2022 
856 |z View Fulltext in Publisher  |u https://doi.org/10.3389/fonc.2022.876120 
520 3 |a Background: Endometrial cancer (EC) is one of the most common gynecologic malignancies in clinical practice. This study aimed to compare the value of diffusion-weighted imaging (DWI), diffusion kurtosis imaging (DKI), and amide proton transfer-weighted imaging (APTWI) in the assessment of risk stratification factors for stage I EC including histological subtype, grade, stage, and lymphovascular space invasion (LVSI). Methods: A total of 72 patients with stage I EC underwent pelvic MRI. The apparent diffusion coefficient (ADC), mean diffusivity (MD), mean kurtosis (MK), and magnetization transfer ratio asymmetry (MTRasym at 3.5 ppm) were calculated and compared in risk groups with the Mann–Whitney U test or independent samples t-test. Spearman’s rank correlation was applied to depict the correlation of each parameter with risk stratification. The diagnostic efficacy was evaluated with receiver operating characteristic (ROC) curve analysis and compared using the DeLong test. A multivariate logistic regression was conducted to explore the optimal model for risk prediction. Results: There were significantly greater MTRasym (3.5 ppm) and MK and significantly lower ADC and MD in the non-adenocarcinoma, stage IB, LVSI-positive, high-grade, and non-low-risk groups (all p < 0.05). The MK and MTRasym (3.5 ppm) were moderately positively correlated with risk stratification as assessed by the European Society for Medical Oncology (EMSO) clinical practice guidelines (r = 0.640 and 0.502, respectively), while ADC and MD were mildly negatively correlated with risk stratification (r = −0.358 and −0.438, respectively). MTRasym (3.5 ppm), MD, and MK were identified as independent risk predictors in stage I EC, and optimal predictive performance was obtained with their combinations (AUC = 0.906, sensitivity = 70.97%, specificity = 92.68%). The results of the validation model were consistent with the above results, and the calibration curve showed good accuracy and consistency. Conclusions: Although similar performance was obtained with each individual parameter of APTWI, DWI, and DKI for the noninvasive assessment of aggressive behavior in stage I EC, the combination of MD, MK, and MTRasym (3.5 ppm) provided improved predictive power for non-low-risk stage I EC and may serve as a superior imaging marker. Copyright © 2022 Jin, Yan, Li, Zhang, Liu, Wang, Zhang, Guo, Wang and Han. 
650 0 4 |a amide proton transfer-weighted imaging 
650 0 4 |a diffusion kurtosis imaging 
650 0 4 |a diffusion-weighted imaging 
650 0 4 |a endometrial cancer 
650 0 4 |a risk factors 
700 1 |a Guo, J.  |e author 
700 1 |a Han, D.  |e author 
700 1 |a Jin, X.  |e author 
700 1 |a Li, Z.  |e author 
700 1 |a Liu, W.  |e author 
700 1 |a Wang, H.  |e author 
700 1 |a Wang, K.  |e author 
700 1 |a Yan, R.  |e author 
700 1 |a Zhang, G.  |e author 
700 1 |a Zhang, M.  |e author 
773 |t Frontiers in Oncology